Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?

Hilleret, Marie Noelle; Larrat, Sylvie; Stanke‐Labesque, Françoise; Leroy, Vincent

doi:10.1016/j.jhep.2011.04.006

Cited by 21 publications

(26 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subsequent studies have confirmed these findings by concurrently measuring virological breakthrough and non-adherence [18,20,[22][23][24], but none provided a consistent definition for non-adherence that is evidence-based. One of the most challenging issues in the field of medication adherence research is the use of varied definitions and arbitrary cut-off points to define adherence to therapies.…”

Section: Factors Associated With Hepatitis B Virus Virological Breaktmentioning

confidence: 99%

See 1 more Smart Citation

Factors associated with HBV Virological Breakthrough

et al. 2017

View full text Add to dashboard Cite

BREAKTHROUGHBackground: Little is known about non-adherence to Hepatitis B virus (HBV) therapy.This study aimed to investigate the relationship between self-reported missed days of anti-viral therapy and HBV virological breakthrough and factors associated with virological breakthrough.Methods: A cross-sectional survey of 211 HBV patients receiving oral anti-viral therapies was undertaken at three tertiary hospitals in Sydney, Australia. Associations between 0 to > 6 missed days in the last 30 days and virological breakthrough (defined as > 10-fold rise in serum HBV DNA above nadir or after achieving virological response in the last 12 months) were examined. Logistic regression analyses determined the number of missed days most strongly associated with virological breakthrough and the associated factors. We report odds ratios and relative risks.Results: Of the 204, 32 participants (15.6%) had quantifiable HBV DNA levels (> 20 IU/mL); 15 (46.8%) of them experienced virological breakthrough. Participants reported never missing medication (n=130, 63.7%) or missing one day (n=23, 11.3%), >one day (n=23, 11.3%), 2-6 days (n=15, 7.3%) and >6 days (n=13, 6.4%). The most discriminating definition of non-adherence was missing > one day of medication

show abstract

Section: Factors Associated With Hepatitis B Virus Virological Breaktmentioning

confidence: 99%

“…anti-viral therapies, recent reports have acknowledged the relationship between nonadherence and virological breakthrough [18,22,23,38]. provides key information to be delivered during patient education and adherence counselling.…”

Section: Relationship Between Days Of Medication Missed and Virologicmentioning

confidence: 99%

Factors associated with HBV Virological Breakthrough

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A presença de proporção aumentada de efeito solo e/ou teto indica capacidade discriminativa baixa do instrumento (86) . (53,72) .…”

Section: Discussionunclassified

“…Vários autores já apontam a adesão à terapia antiviral como a chave para o sucesso terapêutico, diminuindo a resistência às drogas, a carga viral plasmática de VHB e, com isso, os custos com o tratamento (71)(72)(73)(74)(75) .…”

Section: A Adesão Ao Tratamento Na Hepatite B Crônicaunclassified

“…Além disso, o paciente deve assumir responsabilidade como parte do processo de cuidar de sua saúde, através da adesão ao tratamento farmacológico proposto pelo médico, uma vez que a não adesão pode contribuir como causa do desenvolvimento de resistência antiviral, e consequentemente, aumento da carga viral de VHB (46,72,74) .…”

Section: A Adesão Ao Tratamento Na Hepatite B Crônicaunclassified

See 1 more Smart Citation

Validação de um questionário para a avaliação da adesão ao tratamento antiviral em pacientes portadores de hepatite B crônica

Abreu¹

View full text Add to dashboard Cite

Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta‐Analysis

Ford

Scourse

Lemoine

et al. 2018

Hepatology Communications

View full text Add to dashboard Cite

Successful treatment outcomes for chronic hepatitis B virus (HBV) infection requires high levels of adherence to treatment. We searched three databases and abstracts from two conferences up to January 2018 for studies reporting the proportion of patients who were adherent to HBV antiviral therapy and pooled data using random effects meta‐analysis. We included 30 studies, providing data for 23,823 patients. Overall, adherence to treatment was 74.6% (95% confidence interval [CI] 67.1%‐82.1%). Adherence was similar in high‐income settings (75.1%; 95% CI, 65.4%‐85.0%) and in low‐income and middle‐income settings (72.9%; 95% CI, 57.8%‐88.0%). Reported barriers to adherence included forgetting, limited understanding of the importance of adherence, and change to routine. Conclusion: There is a need to reinforce assessment and reporting of adherence as a routine part of HBV care and to assess the extent to which evidence‐based interventions to improve adherence to medication for human immunodeficiency virus [HIV] and other chronic diseases are effective for HBV infection.

show abstract

Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?

Cited by 21 publications

References 3 publications

Factors associated with HBV Virological Breakthrough

Factors associated with HBV Virological Breakthrough

Validação de um questionário para a avaliação da adesão ao tratamento antiviral em pacientes portadores de hepatite B crônica

Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta‐Analysis

Contact Info

Product

Resources

About